ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We present the results of a phase-1 trial of vamotinib in subjects with BCR::ABL1-positive CML failing ≥ 2nd generation TKIs (2G-TKIs) or with BCR::ABL1T315I.